Current recommendations state that antiretroviral therapy (
Introduction
Despite the increasing availability of ART in many parts of the world, a significant proportion of patients are only diagnosed with HIV-1 infection when they already have advanced immune deficiency, defined as the presence of any AIDS-defining opportunistic infections (OIs) or malignancy, or severe immunological impairment (<200 CD4 cells/µL). 1, 2 In the United Kingdom, almost half of individuals newly diagnosed with HIV in 2002 had a CD4 count <200 cells/µL, and only commenced ART at this late state. 3, 4 Similarly, in Spain, between 1998 and 2000, more than one third of AIDS patients were unaware of their HIV infection until one month before diagnosis, and more than 10 percent of these patients died within three months of diagnosis. 2 In Australia and the United States, almost half of all AIDS diagnoses occur in patients diagnosed with HIV infection in the previous three months. 5, 6 The presence of a significant proportion of undiagnosed HIV infections presenting with advanced immune deficiency and OIs prevents ART from having a greater impact on AIDS morbidity and mortality. In particular, non-white individuals, mainly black Africans in Europe and African Americans in the United States, are more likely to present with advanced disease. 7, 8 As a result, the marked reductions observed in HIV-related mortality and morbidity since the introduction of highly active antiretroviral therapy (HAART) have been less apparent in these groups. 4, 8 Although there continues to be debate about the optimal timing of the initiation of ART in patients with mild to moderate immunodeficiency (CD4 count >350 cells/µL), there is consensus that all patients with an AIDS diagnosis or a CD4 count <200 cells/µL should receive HAART regardless of the level of plasma viremia. [9] [10] [11] Studies have consistently shown that the prognosis of patients is better when HAART is initiated before the CD4 count has declined below 200 cells/µL. [12] [13] [14] [15] Current guidelines recommend the use of a maximally suppressive regimen containing a protease inhibitor (PI) or a nonnucleoside reverse transcriptase inhibitor (NNRTI) regardless of the clinical or immunological stage of HIV disease. [9] [10] [11] These recommendations are predominantly based on clinical trials that compared different ARV regimens in patients with mild to moderate immunodeficiency, and which excluded patients with very low CD4 counts or recent OIs. Overall, these trials showed either superior anti-HIV activity of efavirenz (EFV) compared to unboosted PIs [nelfinavir (NFV) and indinavir (IDV)] 16, 17 or boosted PI-containing regimens [saquinavir (SQV) and amprenavir (APV)], 18, 19 or equivalence when compared to an atazanavir (ATV)-based regimen 20 in treatment-naive patients. To date, there have been no randomized trials of a "head-to-head" comparison between EFV and lopinavir/ritonavir (LPV/r), the PI associated with the greatest potency and most durable viral suppression. 21 guide clinicians on the optimal management of these patients. Of note, none of the existing treatment guidelines make any specific treatment recommendations in patients with advanced disease, [9] [10] [11] other than the Spanish guidelines which recommend the use of PI-based HAART in naive patients with CD4 counts <100 cells/µL. 22 Two key questions in the management of patients with advanced HIV disease are: 1) whether the virological and immunological responses to HAART are comparable to those seen in patients with less advanced disease; and 2) whether the evidence for the efficacy of different ARV regimens differs in patients with advanced disease (and therefore whether there is an optimal ARV regimen for this subgroup). Finally, we shall also discuss the potential complications associated with initiating HAART in patients with advanced disease.
Are the virological and immunological responses to HAART impaired in patients with advanced disease?
As would be expected, the risk of developing AIDS after initiation of HAART is greatest in those with the most advanced HIV disease. In an analysis of combined data from several HAART-treated cohorts, the three-year probability of progression to AIDS or death among treatment-naive patients without AIDS and a viral load <100,000 copies/mL was 15.8 percent among those who initiated therapy with a CD4 count between 0 and 50 cells/µL, 12.8 percent with a CD4 count of 50-99 cells/µL, 9.3 percent with a CD4 count of 100-199 cells/µL, and approximately 4 percent among those with a CD4 count >200 cells/µL. 12 Few AIDS events, however, were reported among patients with CD4 counts <50 cells/µL who achieved a CD4 count >200 cells/µL following the initiation of PI-based HAART. 23 However, a further analysis of this cohort data found that baseline CD4 count and viral load were no longer prognostic after the six-month immunological and virological responses were taken into account. This implies that it is the CD4 count and viral load a patient achieves in response to HAART that is important rather than the pre-treatment or nadir value, which is a positive message for patients who, despite advanced disease, have a good treatment response.
Post hoc analyses of four clinical trials 16, 21, [24] [25] [26] and two retrospective cohort studies 18, 27 have examined the impact of baseline CD4 count and/or viral load on responses to HAART. Two randomized trials have reported a higher rate of virological failure among patients with very advanced immunodeficiency. In the 2NN study, a large 48-week trial of stavudine (d4T)/lamivudine (3TC) combined with nevirapine (NVP) and/or EFV, there was an increased risk of virological failure among 140 patients who had a CD4 count <25 cells/µL at baseline compared to 592 patients who had a baseline count >200 cells/µL (hazard ratio [HR] 1.5; p = 0.04). 26 An increased rate of virological failure at 48 weeks was also noted among 69 patients with baseline CD4 counts <50 cells/µL (compared to those with CD4 counts >50 cells/µL) who received treatment with abacavir (ABC)/3TC/NFV, although the rates of virological failure were similar for patients treated with ABC/3TC and fosamprenavir/ritonavir (FPV/r). 24 In contrast, two cohort studies found no differences in virological outcome according to baseline CD4 count, either among patients with baseline CD4 counts <50 cells/µL or >200 cells/µL, 18 or those with baseline CD4 counts <200 cells/µL, compared to 200-349 cells/µL or >350 cells/µL. 27 Similarly, in a four-year follow-up study of patients treated with d4T/3TC and LPV/r, there was no difference in the magnitude of increase in the absolute CD4 count in the 17 patients with a baseline CD4 count <50 cells/µL and the 19 patients with counts of either 50-200 cells/µL or >200 cells/µL. 21 Most studies have consistently reported a lower rate of virological suppression with HAART in patients with advanced disease based on a high baseline viral load, usually >100,000 copies/mL. Patients in the 2NN study who received EFV and/or NVP-based HAART, and who had a baseline viral load of >100,000 copies/mL were 1.63 times (95 percent confidence interval [CI] 1.28-2.07) more likely to experience virological failure than patients with viral loads below this value. 25, 26 Similarly, in another randomized trial, a poorer virological response was observed in patients with baseline viral loads >100,000 copies/mL who received (unboosted) IDV (but not in patients who received EFV/zidovudine [ZDV]/3TC). 16 Two cohort studies have also confirmed either a poorer virological response within eight months of commencing HAART 18 or a slower rate of achieving viral suppression. 27 Overall, the results of clinical trials and cohort studies suggest that only very advanced disease (usually a CD4 count <50 cells/µL or a viral load >100,000 copies/mL) is associated with an impaired response to HAART. Importantly, none of these studies were designed, or statistically powered, to detect differences in CD4 count or virological responses between patients according to various CD4 count strata.
Is there a difference in efficacy of different ARV regimens in patients with advanced disease?
A key question is whether there is evidence for superior efficacy of a specific regimen in patients with advanced disease. Only one randomized trial has been conducted specifically in patients with advanced disease; 28 the other sources of data are subgroup analyses of large trials according to baseline CD4 strata, [24] [25] [26] [29] [30] [31] and data from observational cohort studies. [32] [33] [34] Following is a review of data that has specifically examined the relative efficacy of the different NNRTIs and different PIs, the efficacy of NNRTIs versus PIs, the use of quadrupledrug therapy, and the role of adjunct approaches such as interleukin-2 (IL-2). EFV versus NVP: In the 2NN trial, 1,216 therapy-naive patients were randomized to NVP (once or twice daily), EFV, or EFV plus NVP in combination with d4T and 3TC. More than half the patients had CD4 counts <200 cells/µL, and one third of them had viral loads of >100,000 copies/mL at baseline. Overall, at 48 weeks 62 percent of patients treated with EFV and 56 percent of patients treated with NVP achieved an undetectable viral load (<50 copies/mL). Importantly, in none of the combined CD4 count and plasma viral load strata (<25 cells/µL, 25-200 cells/µL, >200 cells/µL and <100,000 copies/mL or >100,000 copies/mL, respectively) was there a statistically significant difference in the rate of virological failure between NVP and EFV. 26 However, the small number of patients in some strata (only 41 patients had a CD4 count <25 cells/µL and a viral load <100,000 copies/mL) may have been insufficient to detect a difference in efficacy between NVP and EFV. In a further analysis of observational data on 599 patients with a CD4 count <50 cells/µL at treatment initiation, no difference was found in the attainment of a CD4 count >200 cells/µL between NVP-and EFV-treated patients. 32 The successful use of NNRTI-based HAART to treat advanced HIV disease is further supported by a retrospective analysis of 92 ARV-naive patients from Spain with a CD4 count <100 cells/µL (and recent AIDSdefining illnesses in half of the patients) who received EFV. In this cohort, 69 percent attained a viral load <50 copies/mL at 48 weeks, 35 and there was a mean CD4 count increase of 173 cells/µL, which is broadly comparable to the levels reported in less immunosuppressed patients.
PIs: Subgroup analysis of patients with CD4 counts below 50 cells/µL or high viral loads in randomized trials comparing FPV (with or without ritonavir [RTV]) or LPV/r to NFV suggested that FPV and LPV/r may be more efficacious than NFV 24, 29, 30 in advanced immunosuppression, as well as in those with high baseline viral loads. In patients with CD4 counts <50 cells/µL, boosted and unboosted FPV resulted in a higher proportion of patients with an undetectable viral load (<400 copies/mL) at 48 weeks (73 percent and 48 percent of patients respectively compared to 53 percent and 24 percent of NFV-treated patients), 24, 29 while LPV/r treatment was associated with a greater mean CD4 count increase (+268 cells/µL) compared to NFV (+194 cells/µL, p = 0.006). 30 NNRTIs versus PIs: To date, in the three studies that have analyzed the relative efficacy of NNRTIs versus PIs in patients with advanced disease, virtually all PI-treated patients received non-boosted PIs. In an analysis of an observational database of 599 patients initiating HAART with a CD4 count <200 cells/µL, no difference was found between NNRTIs and different PI regimens in attainment of immunological success (a CD4 count >200 cells/µL). 32 However, while the use of unboosted PIs was associated with a somewhat poorer CD4 count response compared to EFV (HR 0.65, 95 percent CI 0.41-1.03, for achieving a CD4 count >200 cells/µL), a trend toward a superior CD4 count response to boosted PIs was noted (HR 1.33, 95 percent CI 0.81-2.16, p = 0.26). 32 In a cohort of 310 ARV-naive patients with CD4 counts <100 cells/µL who commenced HAART, EFV resulted in increased rates of viral suppression compared to non-boosted PIs (69 percent versus 45 percent achieved a viral load <400 copies/mL). 33 However, no difference was noted in the time to CD4 count recovery above 200 cells/µL or the number of clinical events. 33 A higher rate of initial viral suppression in patients treated with EFV compared to (predominantly) unboosted PIs was also noted among 142 patients with CD4 counts below 200 cells/µL in the Swiss HIV Cohort Study (HR 1.75, 95 percent CI 1.34-2.29). 34 Together, these studies suggest that EFV-based HAART is at least comparable to PI-based HAART in patients with advanced disease, but that EFV may result in higher rates of virological suppression when compared to non-boosted PIs. Reduced pill burden, superior pharmacokinetic properties, and different sideeffect profiles of NNRTIs relative to non-boosted PIs may have contributed to the observed differences in efficacy. There remains insufficient data to draw any conclusions on the relative efficacy of EFV (or NVP) versus boosted PIs in patients with advanced disease.
Triple-NRTI therapy: In a randomized controlled study, triple-NRTI therapy was found to be significantly less active than EFV-based ART in patients with CD4 counts <200 cells/µL and particularly below 100 cells/µL. 31 Since patients with advanced disease stand to gain most from maximally suppressive therapy, the use of triple-NRTIs alone is not recommended. [9] [10] [11] Quadruple therapy: Given the substantially higher risk for the development of OIs and the slower rate of viral suppression observed in some studies of patients with advanced immunodeficiency, 12 an important goal of therapy in such patients is to rapidly achieve maximal and durable virological suppression and immune reconstitution to a CD4 count above 200 cells/µL. One potential approach to achieve this is the use of a fourdrug regimen, by combining NNRTIs with either a triple-NRTI backbone or with a PI and two NRTIs (eg, triple class). While no comparative studies on the use of an NNRTI/triple-NRTI regimen in patients with advanced disease exist, a study of ZDV/3TC/ABC (Trizivir) in combination with EFV in patients with baseline CD4 counts <50 cells/µL found that 83 percent attained a viral load <50 copies/mL, and there was a median CD4 increase of 190 cells/µL in the 35 patients who completed 48 weeks of therapy. 36 However, 20 patients failed to complete 48 weeks of treatment for a variety of reasons, which raises concerns about the ability to generalize these findings. 36 AIDS Clinical Trials Group (ACTG) study 388 was a randomized study of EFV as an adjunct to IDV, 3TC, and ZDV in patients with advanced disease as defined by a CD4 count <200 cells/µL or a plasma viral load above 80,000 copies/mL. 28 This study showed that patients who received EFV in addition to an IDV-containing HAART regimen had both reduced rates of virological failure (HR 0.65; 95 percent CI 0.42-0.99), reduced relapse rates following initial viral suppression below 200 copies/mL (HR 0.45; 95 percent CI 0.25-0.84), and lower rates of treatment failure (defined as the development of virological failure, an AIDS-defining event or death, whichever occurred first). 28 However, since this four-drug regimen was not compared with EFV plus two NRTIs, superiority of this regimen over a standard EFV-containing HAART regimen cannot be inferred. Two additional studies have examined the value of adding a PI to an NNRTI-based regimen. 37, 38 In ACTG 384, the addition of NFV to a regimen of EFV, 3TC, and ZDV did not result in higher initial rates of undetectable viral load or more sustained viral suppression. 38 However, in a further trial, the addition of a PI for 24 to 32 weeks to an NNRTI-based regimen increased the proportion of patients with undetectable viral load at 48 weeks from 65 percent to 81 percent (p = 0.07). 37 In neither of these studies was the addition of a PI associated with an enhanced rise in CD4 count. 37, 38 In addition, since both these studies included patients with CD4 counts above 200 cells/µL (the median CD4 counts at baseline in these studies were approximately 275 cells/µL and 160 cells/µL, respectively), it remains uncertain whether these findings are applicable to patients with advanced disease. Overall, these data show a more durable virological suppression, but not a greater CD4 count rise in patients with advanced disease who receive quadruple HAART. Additional studies will be required to determine whether these benefits outweigh the increased pill burden and risk of long-term toxicities.
Immunomodulating agents: Another as yet experimental approach in patients with advanced disease would be to use IL-2 in addition to HAART in an attempt to further boost CD4 counts in patients with severe immunosuppression. The administration of 12 to 80 weeks of IL-2 has been associated with significantly greater increase in CD4 count compared to the use of HAART alone in patients with CD4 counts <200 cells/µL and low or undetectable viral loads. [39] [40] [41] In these studies, multiple cycles of IL-2 immunotherapy were added to ARV regimens in patients who had failed to show substantial increases in their CD4 counts. In the largest trial, 81 percent of the 34 patients randomized to IL-2 plus HAART versus 33 percent of the 36 patients in the HAART-only arm achieved a CD4 count >200 cells/µL at week 24 (p < 0.0001). 39 However, there remains insufficient data to ascertain whether the immunological benefit confers protection from the development of new AIDS events. Nonetheless, these studies suggest that IL-2 is a potential management option in patients with advanced HIV disease who have experienced a suboptimal CD4 count increase despite complete virological suppression in response to HAART.
Risks of HAART in patients with advanced HIV disease
Patients with advanced HIV infection, and particularly those with very low CD4 counts (<50 cells/µL) are at a substantially increased risk of death or developing OIs. 42 When such AIDS events occur in these patients, they are most often observed in the initial two to four months after initiating HAART. 23, 43 However, the observed CD4 count recovery that follows viral suppression by HAART results in a markedly reduced risk of disease progression. 42 Taken together, this suggests that HAART should be initiated as soon as possible in patients who present with advanced disease. However, there are other considerations which complicate the administration of HAART in patients with advanced disease. These patients are more likely to present with active OIs and other co-morbidities such as anemia, malabsorption, paralytic ileus, renal and hepatic impairment, and impaired cognition. This presents challenges with respect to an increased risk of drug toxicities and drug interactions, which in turn may impact the ability to tolerate the initial regimen and levels of adherence. For example, in one cohort study of 70 patients with advanced HIV infection, 24 percent were unable to tolerate their ARV regimen. 44 A further challenge is the development of immune reconstitution inflammatory syndrome (IRIS), a syndrome in which subclinical or existing infections occur with a paradoxical deterioration in clinical status in association with HAART-induced recovery of immune function. The clinical spectrum of IRIS is diverse, and IRIS in response to Mycobacterium tuberculosis, Cryptococcus neoformans, cytomegalovirus, and Pneumocystis carinii pneumonia have all been reported. 45 One cohort study of 132 patients who commenced HAART found that patients who developed IRIS had significantly lower mean CD4 counts (88 versus 237 cells/µL) and higher viral loads (5.36 versus 4.88 log 10 copies/mL) at baseline compared to patients who did not develop IRIS, and that a lower baseline CD4 count was found to be a highly significant (p = 0.003) predictor of developing IRIS. 46 Although the management of IRIS remains poorly defined, non-steroidal anti-inflammatory drugs and glucocorticosteroids have been used with variable success to blunt the severity of IRIS. 45, 47 At present, no randomized trials have evaluated the relative benefits and risks of immediate versus deferred initiation of HAART in patients with advanced disease with active OIs, and in general, decisions about the timing of HAART and choice of regimen is based on pragmatic considerations, such as number of concomitant medications, on a case-by-case basis.
Summary
Few studies have specifically examined treatment strategies for patients with advanced HIV infection, as defined by an AIDS diagnosis, or a CD4 count <200 cells/µL. Antiretroviral therapy should be commenced as a matter of urgency, and consist of maximally suppressive combination therapy. Overall, some studies suggest a less optimal initial or less durable virological response to HAART among patients with very advanced disease, although a substantial proportion achieves a satisfactory virological and immunological outcome. Among patients with advanced disease, NNRTI-based regimens achieve a higher rate of durable viral suppression compared to non-boosted PIs, and EFV and NVP appear similar in efficacy. Across the PIs, FPV and LPV/r are superior to NFV in patients with low CD4 counts or a high viral load. Some preliminary data suggest an improved virological outcome with fourdrug/triple-class regimens, although this is likely to be associated with an increased rate of toxicities. ■
